Latest news with #TourmalineBio
Yahoo
28-05-2025
- Business
- Yahoo
H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results
On May 27, H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Tourmaline Bio, Inc. (NASDAQ:TRML) while keeping the price target at $50. This comes after the company released promising results from the Phase 2 TRANQUILITY trial of Pacibekitug. A scientist in a white lab coat working at a bench with biopharmaceutical equipment. Analyst Chen noted the results from the Phase 2 TRANQUILITY trial showed a significant reduction in high-sensitivity C-reactive protein (hs-CRP) levels in patients with kidney disease. The candidate also achieved a rapid and durable reduction in hs-CRP compared to the existing Ziltivekimab. Chen believes this can increase the potential market share of Tourmaline Bio, Inc.'s (NASDAQ:TRML) Pacibekitug. Tourmaline Bio, Inc. (NASDAQ:TRML) is a late-stage clinical biotechnology company developing treatments for life-altering immune and inflammatory diseases. Pacibekitug (TOUR006), is the company's lead product. It is a fully human monoclonal antibody designed to have a long half-life, high binding affinity to IL-6, and low immunogenicity. While we acknowledge the potential of TRML as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRML and that has 100x upside potential, check out our report about the . READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)
On Wednesday, May 21, BMO Capital Markets reaffirmed its 'Outperform' rating on Tourmaline Bio, Inc. (NASDAQ:TRML) with a price target of $35. The firm believes that the market's negative reaction to Phase II data for the company's drug, Paci, was excessive. BMO believes that Paci, which is given on a quarterly basis (Q3M), is comparable to that of a competitor's monthly treatment (Q1M). This could make Paci a best-in-class option. A scientist in a laboratory coat studying a test tube, showing the biotechnology company's clinical-stage therapies. The analyst pointed out that some concerns caused Tourmaline Bio, Inc.'s (NASDAQ:TRML) share price to drop. These included Paci's placebo-adjusted profile showing about a 73% reduction in C-reactive protein (CRP), which is less than about 84% for the competitor, along with a COVID-related death. However, according to BMO, low levels of interleukin-6 (IL-6), linked to better COVID outcomes, should also be taken into account when determining Paci's profile. BMO also reviewed pharmacokinetic (PK), pharmacodynamic (PD), and safety data, arguing that these further support Paci's unique profile and should help ease investor concerns. Tourmaline Bio, Inc. (NASDAQ:TRML) is a late-stage clinical biotechnology company. It focuses on developing transformative medicines to improve the lives of patients with life-altering immune and inflammatory diseases. While we acknowledge the potential of TRML as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TRML and that has a 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York. Dr. Bhatt also serves as the Chair of Tourmaline's Cardiovascular Scientific Advisory Board (for which he is compensated). To register for this event, please click here or visit the 'Events and Presentations' section of Tourmaline's website. A replay will be available on Tourmaline's website following the event. About Tourmaline Bio:Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline's lead asset is pacibekitug. For more information, please visit or follow us on LinkedIn or X. About Pacibekitug:Pacibekitug is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Excluding ongoing trials, pacibekitug was previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is currently developing pacibekitug in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) as its first two indications, with plans to expand into abdominal aortic aneurysm (AAA) and additional diseases in the future. Media Contact:Scient PRSarah MishekSMishek@ Investor Contact:Meru AdvisorsLee M. Sternlstern@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-04-2025
- Business
- Yahoo
Here's Why We're Not Too Worried About Tourmaline Bio's (NASDAQ:TRML) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So, the natural question for Tourmaline Bio (NASDAQ:TRML) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. First, we'll determine its cash runway by comparing its cash burn with its cash reserves. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. You can calculate a company's cash runway by dividing the amount of cash it has by the rate at which it is spending that cash. In December 2024, Tourmaline Bio had US$258m in cash, and was debt-free. Looking at the last year, the company burnt through US$77m. That means it had a cash runway of about 3.3 years as of December 2024. A runway of this length affords the company the time and space it needs to develop the business. You can see how its cash balance has changed over time in the image below. View our latest analysis for Tourmaline Bio Tourmaline Bio didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. The skyrocketing cash burn up 175% year on year certainly tests our nerves. That sort of spending growth rate can't continue for very long before it causes balance sheet weakness, generally speaking. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. Given its cash burn trajectory, Tourmaline Bio shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash and drive growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate). Tourmaline Bio has a market capitalisation of US$411m and burnt through US$77m last year, which is 19% of the company's market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted. Even though its increasing cash burn makes us a little nervous, we are compelled to mention that we thought Tourmaline Bio's cash runway was relatively promising. While we're the kind of investors who are always a bit concerned about the risks involved with cash burning companies, the metrics we have discussed in this article leave us relatively comfortable about Tourmaline Bio's situation. On another note, Tourmaline Bio has 3 warning signs (and 2 which are potentially serious) we think you should know about. Of course Tourmaline Bio may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Associated Press
03-03-2025
- Business
- Associated Press
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Leerink's Global Healthcare Conference 2025, Miami Fireside Chat Tuesday, March 11, 2025, at 4:20 pm ET A live webcast and replay, when available, will be available under 'Events and Presentations' in the News & Investors section of the Tourmaline Bio website at About Tourmaline Bio Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline's lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline Bio and pacibekitug, please visit or follow us on LinkedIn or X. Media Contact Scient PR Sarah Mishek Investor Contact Meru Advisors Lee M. Stern
